ProCE Banner Activity

Phase I Study to Assess the Effect of Trastuzumab Deruxtecan on QTc Interval and Pharmacokinetics in HER2-Expressing Metastatic or Unresectable Breast Cancer

Slideset Download
Conference Coverage
In heavily pretreated patients with HER2-expressing breast cancer, trastuzumab deruxtecan did not result in clinically meaningful prolongation of QTc interval and was associated with a manageable safety profile and antitumor activity.

Released: December 20, 2019

Expiration: December 18, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Genentech TEXT Only

Merck Sharp & Dohme Corp.

Puma Biotechnology, Inc.

Seagen